MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jjcc.2017.10.018

Медицинская библиотека · Journal of cardiology · 2017

Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis.

Zeng Xiaofang, Lincoff A Michael, Schulz-Schüpke Stefanie, Steg Philippe Gabriel, Elbez Yedid, Mehran Roxana, Stone Gregg W, McAndrew Thomas, Lin Jianhui, Zhang Xindan, Shi Wenhai, Lei Han, Jing Zhicheng, Huang Wei

Сравнительное исследованиеСтатьяМетаанализПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Patients with chronic kidney disease (CKD) have elevated bleeding and ischemic outcomes. We aim to assess the short- and long-term efficacy and safety of bivalirudin compared to heparin plus glycoprotein IIb/IIIa inhibitors (GPIs) in coronary artery disease (CAD) patients with CKD.

METHODS

Randomized trials were searched in PubMed, Cochrane, and Embase databases up to January 2017. Among the trials retrieved, efficacy endpoints were defined as mortality, myocardial infarction (MI), repeat revascularization, stent thrombosis, and major adverse cardiac events (MACEs). Safety endpoints were reported as non-coronary artery bypass grafting (CABG) related major bleeding and thrombolysis in myocardial infarction (TIMI) major bleeding. Risk ratio (RR) and 95% confidence interval (CI) were calculated for each outcome using a fixed effect model.

RESULTS

Five studies with a total of 3796 patients were included. In short-term follow up (30 days), bivalirudin significantly reduced non-CABG related major bleeding (p=0.0004) and TIMI major bleeding (p=0.007) compared to heparin plus GPIs. No significant differences were observed in rates of mortality, MI, repeat revascularization, stent thrombosis, and MACEs between the two groups in short- and long-term follow up (6 months to 3 years). In patients with ST elevated myocardial infarction (STEMI) with concurrent CKD, the decreased non-CABG related major bleeding (p=0.04) without increasing ischemic events was also observed after short-term follow up.

CONCLUSIONS

(1) Bivalirudin is safer than and as effective as heparin plus GPIs in CAD patients with CKD. (2) Impaired renal function does not affect the safety benefits of bivalirudin. (3) Similar efficacy profiles were identified between the two groups after both short- and long-term follow up in the CAD patients with CKD.

Для цитирования: Zeng Xiaofang, Lincoff A Michael, Schulz-Schüpke Stefanie, Steg Philippe Gabriel, Elbez Yedid, Mehran Roxana, Stone Gregg W, McAndrew Thomas, Lin Jianhui, Zhang Xindan, Shi Wenhai, Lei Han, Jing Zhicheng, Huang Wei. Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis.. Journal of cardiology. 2017. DOI: 10.1016/j.jjcc.2017.10.018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.